{"name":"NewLink Genetics Corporation","slug":"newlink-genetics-corporation","ticker":"","exchange":"","domain":"linkp.com","description":"","hq":"Ames","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HyperAcute-Pancreas Immunotherapy","genericName":"HyperAcute-Pancreas Immunotherapy","slug":"hyperacute-pancreas-immunotherapy","indication":"Metastatic pancreatic cancer (in combination with checkpoint inhibitor)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NLG802","genericName":"NLG802","slug":"nlg802","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"HyperAcute-Pancreas Immunotherapy","genericName":"HyperAcute-Pancreas Immunotherapy","slug":"hyperacute-pancreas-immunotherapy","phase":"phase_3","mechanism":"HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor.","indications":["Metastatic pancreatic cancer (in combination with checkpoint inhibitor)"],"catalyst":""},{"name":"NLG802","genericName":"NLG802","slug":"nlg802","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQaDNkQVlyX1YyNl91WmZwa2ozdFo1YmhRSlJEREdxb19mNTlrWThIUDhaWVMzRENZcDFFWHMtT0V2ajVZSlNCTS0zck9YcWVYeEl6U0hURlNqeHNDQ2c3amp3NDhGSk5JVUsyWmJ2YzgwaDJlNDllSjI0VWJKSW9US2t1SXN6TDFWTkVEaEx0b2dwVk9wbkg0UG1n?oc=5","date":"2025-10-30","type":"pipeline","source":"BioSpace","summary":"Vistagen Appoints Paul Edick to its Board of Directors - BioSpace","headline":"Vistagen Appoints Paul Edick to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdkdsQkhpbFExaHdldEpHN2JMejAxSi1JZ3MwZEI4RnQtMHBvU1JQUTZjMm9zVHFiRkZzVy1vdDlaNEQ4XzNjalNjd01jYXVRZVlrMkxuT2xGMjlGQUk2OTZ2VXpYMmhlYkRKa0xkTkRON2YyRG1XMVRhNWhsazZGWnFVX1NiXzRaM2V5Tl8zMnpSakhWSXFNVEVvNENMcWxxMlE?oc=5","date":"2024-05-03","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout - Fierce Biotech","headline":"Chutes & Ladders—BridgeBio oncology execs take the reins of new spinout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQcFdNWlBhaUh1VUx2WXh6NTR1dk1pbVJtZF9rWlRvOHhLeVNMWTZaQl9ySFF1OV9iMHVfWFBoZEN1Yl9zdzFMVlhPbGJCUE1fX0hIbFhseFp6blNybFhidUVBbEtzS3p1b2JPdnNVM3laYVFrdDNCLU8xZ2R6UWh3QktJZ1FlS2FTZTR3TkhWN1VlVmYtTXFFTU1lRQ?oc=5","date":"2020-01-07","type":"pipeline","source":"statnews.com","summary":"‘Against all odds’: The inside story of how scientists across three continents produced an Ebola vaccine - statnews.com","headline":"‘Against all odds’: The inside story of how scientists across three continents produced an Ebola vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVzdEb1hpbnpBNzJXblJMUVR6VXFwOXpxeE8yX2ZIeS1QbFc3M3R3dHQ2M1A4eW5selcwMGdpTHBFUnRXTUNJcXhMX24zdy1HVE9NbUZwNFZJSkRfUVhRSHVFaGJ2RkF4ZXEwYVBFMF9SZGtqYUVqd2JfT3dNS2ZLX2pGUXRTeXFvWlp5LURqVGFqbW1DSVpGVUxxbw?oc=5","date":"2019-10-01","type":"deal","source":"BioPharma Dive","summary":"NewLink’s two-decade run ends in reverse merger, layoffs - BioPharma Dive","headline":"NewLink’s two-decade run ends in reverse merger, layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbE0yY1oxWUk5VWFtOUdqeTluYmxCRlpsTG40eGdIY2ZMVGJmVGRBRmFtcGZyNkg3d1d3RTk4T0drTFFteXlOaFpoZVF1eEtsOHU0VHZWOHQ3V1hpa3V0VVkyUzBwQmtERWZPMkRZLXJzZ3VwZlB6bDB1YnpORm1tUXUwaWhIVEVSa3VMZHlabWtDODRhcUFWbV9aSkR1dEF0aldicEN6bGtWRWx2YWM0cGN1TQ?oc=5","date":"2019-08-13","type":"pipeline","source":"PBS","summary":"Behind the Life-saving Ebola Vaccine is a Story of Missed Opportunity - PBS","headline":"Behind the Life-saving Ebola Vaccine is a Story of Missed Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOLXdRWEp3RzN3ZTlfOV9VYXZnSnR6MmQ4SVBoc3Jpc0dRczZPdFYydGhrX21HM1pHaEsxZnBWdGtQamR0YV9aZ1JrVEh1M1NjSFFUQ3V5cG9EVXVCWE1mUU1FQ2pLYS1sQjl3emRwNkFERzl0TllBU1U4RkY3dVNlVXBXMW5FZENLNTcweTQtc0htNE4xMFVSSnpOTGh5TjFyMEc5Sw?oc=5","date":"2016-08-02","type":"pipeline","source":"hamilton.edu","summary":"Paul Edick ’77 Joins Sucampo Pharmaceuticals, Inc. Board of Directors - hamilton.edu","headline":"Paul Edick ’77 Joins Sucampo Pharmaceuticals, Inc. Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPWmRCYWtPSHRsUDAtVXJSeFppNHNWMkFYNmQxNDJuN01tc2plLUowNUVFOXZsRmRfdnF0ZV85azZkLTVqUDA4NWtnUWtwb0hYdVVsdU9MSzgzSzNieTRXUVRCbktERVprNjJFYU9oUWtzS3lOb2F3NDF4SzczWHNLNGV2cVdPSFZvOEMyaFFFUldkR3hFY2RzNXZEZWxMQQ?oc=5","date":"2016-06-10","type":"pipeline","source":"The Motley Fool","summary":"Why NewLink Genetics Corporation Dropped 27.6% in May - The Motley Fool","headline":"Why NewLink Genetics Corporation Dropped 27.6% in May","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMFRhUUp1VDdEeVVLdVVnX0VLY3dzejZnVGlMRDh4bzdVWHdGZGU5X3ltaGU4U3pXaEtlRndBeGRiM1EwOVFaUFlhdnNOODBmajhaMmtLQ1VYS1VhVkdxS2E1bkt3U052LUJXSFdCOFZMR2Y0eWRaVEJrdkJkMUUwY1BlUWUwanh5RmtNOHEzVUg3dUl3MnB5X05MSHJNRW52cHBQY1dmWVBWYm9WelpNRkN2NnM1LTBsb1E?oc=5","date":"2016-05-10","type":"trial","source":"BioPharma Dive","summary":"NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure - BioPharma Dive","headline":"NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPQ2RkbnRQQlMzZnlBM2Nkd1BPSUtTdk4wU3JqaVk2ek15a0N4VXVOaTVJWGtBckljRWlzR1V4YmxlSnl5eHVqWTlkNkJaR21ydVZtNEd4WUtjRkNXZmJpY3ZJT2lZVm9uQ25Lb01mTEREZ2Z6M1VSTER2OHlHQ2hSa0dXUzhkbUtpRXRfNXMwRnlCSmtaWjNmMm1nVQ?oc=5","date":"2016-04-18","type":"pipeline","source":"Fierce Pharma","summary":"DOD awards NewLink Genetics $2.8M to develop filovirus jab - Fierce Pharma","headline":"DOD awards NewLink Genetics $2.8M to develop filovirus jab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbXhkT3ZZTzFZZUZWRzcwTXlmVldmSDBjUnRqR0l1dld5YS1vb3hCNTlMUU5MYW5qY1BWUXFFSEhpZXNnWTMyb2NHWFdRdUdacE1QdDVyMnhYd0liaS1KOExfSjF5RlV3bVpCMlVzd01SNFlJc2g0RVpWeE1aNnlYZUJyLTRvcFEyRURBRjJLbWY2Qk5mWUhVUk1heTlTa2NueVZScg?oc=5","date":"2016-01-20","type":"pipeline","source":"Gavi, the Vaccine Alliance","summary":"Ebola vaccine purchasing commitment from Gavi to prepare for future outbreaks - Gavi, the Vaccine Alliance","headline":"Ebola vaccine purchasing commitment from Gavi to prepare for future outbreaks - Gavi, the Vaccine Alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPQk1CdExqcnY3T2VKRWJlWEdvZWhIX3FTTjZvbDFRWFVBaWhodllVbXRkU1JCMFRmLUZkRGFPdTNGU1g1TEFvdVJlc0E4WnZkTWNBX2R6TUdCUWxNaFJhSU51bk85UUI3dHRkeEltMlBESjBzbDMzVTV3d3VpbDAyUXdsNzhsS3pRN2c?oc=5","date":"2014-11-24","type":"deal","source":"CIDRAP","summary":"NewLink, Merck deal boosts prospects for Ebola vaccine - CIDRAP","headline":"NewLink, Merck deal boosts prospects for Ebola vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPZmdud2RBNWxzRHhyc2Y4Z2Rhd0pPeV9icTBJV21ScWtnRGtrMjBMajBRaE5obHRQVkVXdTNVSkpfN0NVQk5SUHNyRm1qYXB2YmQyNjk4NThwV0FfTThHYnhoSkFxdkFZY0otdnJLUVdaT1ZTQVNLZlQ0OWNuMmdjQmZoY2JHS25iaWhfRGRKQ2VyaU4wYkZmMVdHWFQyczE1NjR2b3hCaVFOb3RBM0Q5X1I2cmk?oc=5","date":"2014-08-05","type":"pipeline","source":"The Des Moines Register","summary":"Ames' NewLink Genetics to work on Ebola vaccine - The Des Moines Register","headline":"Ames' NewLink Genetics to work on Ebola vaccine","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}